Sophie Laurent

Prof. Sophie Laurent

University of Mons-UMONS
orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2018 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
TVThomas Vangijzegem
Thomas Vangijzegem
DSDimitri Stanicki
Dimitri Stanicki
Sophie LaurentSophie Laurent
Sophie Laurent
Introduction: For many years, the controlled delivery of therapeutic compounds has been a matter of great interest in the field of nanomedicine. Among the wide amount of drug nanocarriers, magnetic iron oxide nanoparticles (IONs) stand out from the crowd and constitute robust nanoplatforms since they can achieve high drug loading as well as targeting abilities stemming from their remarkable properties (magnetic and biological properties). These applications require precise design of the nanoparticles regarding several parameters which must be considered together in order to attain highest therapeutic efficacy. Areas covered: This short review presents recent developments in the field of cancer targeted drug delivery using magnetic nanocarriers as drug delivery systems. Expert opinion: The design of nanocarriers enabling efficient delivery of therapeutic compounds towards targeted locations is one of the major area of research in the targeted drug delivery field. By precisely shaping the structural properties of the iron oxide nanoparticles, drugs loaded onto the nanoparticles can be efficiently guided and selectively delivered towards targeted locations. With these goals in mind, special attention should be given to the pharmacokinetics and in vivo behaviour of the developed nanocarriers.

26 May 2014 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
Sophie LaurentSophie Laurent
Sophie Laurent
Amirata Saei DibavarAmirata Saei Dibavar
Amirata Saei Dibavar
SBShahed Behzadi
Shahed Behzadi
APArash Panahifar
Arash Panahifar
Morteza MahmoudiMorteza Mahmoudi
Morteza Mahmoudi
(2014). Superparamagnetic iron oxide nanoparticles for delivery of therapeutic agents: opportunities and challenges. Expert Opinion on Drug Delivery: Vol. 11, No. 9, pp. 1449-1470.

10 January 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
TVThomas Vangijzegem
Thomas Vangijzegem
VLValentin Lecomte
Valentin Lecomte
ITIndiana Ternad
Indiana Ternad
LLLevy Van Leuven
Levy Van Leuven
RMRobert N. Muller
Robert N. Muller
Sophie LaurentSophie Laurent
Sophie Laurent
Despite significant advances in cancer therapy over the years, its complex pathological process still represents a major health challenge when seeking effective treatment and improved healthcare. With the advent of nanotechnologies, nanomedicine-based cancer therapy has been widely explored as a promising technology able to handle the requirements of the clinical sector. Superparamagnetic iron oxide nanoparticles (SPION) have been at the forefront of nanotechnology development since the mid-1990s, thanks to their former role as contrast agents for magnetic resonance imaging. Though their use as MRI probes has been discontinued due to an unfavorable cost/benefit ratio, several innovative applications as therapeutic tools have prompted a renewal of interest. The unique characteristics of SPION, i.e., their magnetic properties enabling specific response when submitted to high frequency (magnetic hyperthermia) or low frequency (magneto-mechanical therapy) alternating magnetic field, and their ability to generate reactive oxygen species (either intrinsically or when activated using various stimuli), make them particularly adapted for cancer therapy. This review provides a comprehensive description of the fundamental aspects of SPION formulation and highlights various recent approaches regarding in vivo applications in the field of cancer therapy.

16 April 2015 in Contrast Media & Molecular Imaging
Verified
Journal Article
Closed access
PDF file
Shahriar SharifiShahriar Sharifi
Shahriar Sharifi
HSHajar Seyednejad
Hajar Seyednejad
Sophie LaurentSophie Laurent
Sophie Laurent
FAFatemeh Atyabi
Fatemeh Atyabi
Amirata Saei DibavarAmirata Saei Dibavar
Amirata Saei Dibavar
Morteza MahmoudiMorteza Mahmoudi
Morteza Mahmoudi

1 December 2009 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
Sophie LaurentSophie Laurent
Sophie Laurent
SBS. Boutry
S. Boutry
IMI. Mahieu
I. Mahieu
LEL. Vander Elst
L. Vander Elst
RMR. N. Muller
R. N. Muller
Superparamagnetic iron oxide nanoparticles can be used for numerous applications such as MRI contrast enhancement, hyperthermia, detoxification of biological fluids, drug delivery, or cell separation. In this work, we will summarize the chemical routes for synthesis of iron oxide nanoparticles, the fluid stabilization, and the surface modification of superparamagnetic iron oxide nanoparticles. Some examples of the numerous applications of these particles in the biomedical field mainly as MRI negative contrast agents for tissue-specific imaging, cellular labeling, and molecular imaging will be given. Larger particles or particles displaying a non-neutral surface (thanks to their coating or to a cell transfection agent with which they are mixed) are very useful tools, although the cells to be labeled have no professional phagocytic function. Labeled cells can then be transplanted and monitored by MRI in a broad spectrum of applications. Direct in vivo magnetic labeling of cells is mainly performed by intravenous injection of long-circulating iron oxide-based MRI contrast agents, which can extravasate and/or undergo a cellular uptake in an amount sufficient to allow an MRI visualization of areas of interest such as inflamed regions or tumors. Particles with long circulation times, or able to induce a strong negative effect individually have been also modified by conjugation to a ligand, so that their cellular uptake, or at least their binding to the cell surface, could occur through a specific ligand-receptor interaction, in vivo as well as in vitro. Thus, experimentally as well as in a few trials on humans, iron oxide particles currently find promising applications.

26 October 2023 in Molecules
Verified
Journal Article
Open access
PDF file
CHCeline Henoumont
Celine Henoumont
MDMarie Devreux
Marie Devreux
Sophie LaurentSophie Laurent
Sophie Laurent
MRI contrast agents are required in the clinic to detect some pathologies, such as cancers. Nevertheless, at the moment, only small extracellular and non-specific gadolinium complexes are available for clinicians. Moreover, safety issues have recently emerged concerning the use of gadolinium complexes; hence, alternatives are urgently needed. Manganese-based MRI contrast agents could be one of these alternatives and increasing numbers of studies are available in the literature. This review aims at synthesizing all the research, from small Mn complexes to nanoparticular agents, including theranostic agents, to highlight all the efforts already made by the scientific community to obtain highly efficient agents but also evidence of the weaknesses of the developed systems.